New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

N106, SERCA2a SUMOylation Activator

Overview
Catalog # bs-60271c-2-mg-solid
Product Name N106, SERCA2a SUMOylation Activator
Specifications
Storage Buffer Powder
Storage Condition Store in dry, dark place at -20C for 1 year.
Target
Product Information Molecular Weight: 354.38

Formula: C17 H14 N4 O3 S

CAS Number: 862974-25-2

InChi Key: FBCSWQRNKAYAGY-UHFFFAOYSA-N

InChi: InChI=1S/C17H14N4O3S/c1-22-11-8-6-10(7-9-11)15-20-21-16(24-15)19-17-18-14-12(23-2)4-3-5-13(14)25-17/h3-9H,1-2H3,(H,18,19,21)

Smiles: COC1=CC=CC2SC(NC3=NN=C(O3)C3C=CC(=CC=3)OC)=NC=21

Purity: 98.0

Solubility: DMSO up to 50 mM

Appearance: Solid Power.

Shelf Life: 1.0 years
Description N106 is a potent SERCA2a SUMOylation activator, which increases SUMOylation of SERCA2a. Decreased activity and expression of the cardiac sarcoplasmic reticulum calcium ATPase (SERCA2a), a critical pump regulating calcium cycling in cardiomyocyte, are hallmarks of heart failure. The small ubiquitin-like modifier type 1 (SUMO-1) is a regulator of SERCA2a and the gene transfer of SUMO-1 in rodents and large animal models of heart failure could restore cardiac function. N106 directly activates the SUMO-activating enzyme, E1 ligase, and triggers intrinsic SUMOylation of SERCA2a. There is a pocket on SUMO E1 likely to be responsible for N106's effect. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure. N106 may serve as a good tool compound to validate a potential therapeutic strategy for treatment of heart failure.